Clinical Trial Update: Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for Cis-urocanic acid (Cis-UCA) in patients with primary or recurrent non-muscle invasive bladder cancer; study status is COMPLETE…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Cis-urocanic acid (Cis-UCA) (cis-urocanic acid)

Snippet

Sponsor: BioCis Pharma Ltd | Conditions: Non-muscle Invasive Bladder Cancer | Phase 1 | Status: COMPLETED